79 related articles for article (PubMed ID: 19424100)
1. Evaluation of different normalization procedures for the calculation of the standardized uptake value in therapy response monitoring studies.
Vriens D; de Geus-Oei LF; van Laarhoven HW; Timmer-Bonte JN; Krabbe PF; Visser EP; Oyen WJ
Nucl Med Commun; 2009 Jul; 30(7):550-7. PubMed ID: 19424100
[TBL] [Abstract][Full Text] [Related]
2. Metabolic activity measured by FDG PET predicts pathological response in locally advanced superior sulcus NSCLC.
Bahce I; Vos CG; Dickhoff C; Hartemink KJ; Dahele M; Smit EF; Boellaard R; Hoekstra OS; Thunnissen E
Lung Cancer; 2014 Aug; 85(2):205-12. PubMed ID: 24854401
[TBL] [Abstract][Full Text] [Related]
3. Chemotherapy response evaluation with 18F-FDG PET in patients with non-small cell lung cancer.
de Geus-Oei LF; van der Heijden HF; Visser EP; Hermsen R; van Hoorn BA; Timmer-Bonte JN; Willemsen AT; Pruim J; Corstens FH; Krabbe PF; Oyen WJ
J Nucl Med; 2007 Oct; 48(10):1592-8. PubMed ID: 17873138
[TBL] [Abstract][Full Text] [Related]
4. Ratio of standardized uptake value on PET helps predict response and outcome after chemotherapy in advanced non-small cell lung cancer.
Kaira K; Endo M; Asakura K; Tsuya A; Nakamura Y; Naito T; Murakami H; Takahashi T; Yamamoto N
Ann Nucl Med; 2010 Dec; 24(10):697-705. PubMed ID: 20824397
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of FDG uptake in early stage non-small cell lung cancer.
Hanin FX; Lonneux M; Cornet J; Noirhomme P; Coulon C; Distexhe J; Poncelet AJ
Eur J Cardiothorac Surg; 2008 May; 33(5):819-23. PubMed ID: 18374589
[TBL] [Abstract][Full Text] [Related]
6. Correlation of [18F]-2-fluoro-deoxy-D-glucose positron emission tomography standard uptake values with the cellular composition of stage I nonsmall cell lung cancer.
Christensen JD; Colby TV; Patz EF
Cancer; 2010 Sep; 116(17):4095-102. PubMed ID: 20533438
[TBL] [Abstract][Full Text] [Related]
7. The prognostic value of 18F-fluorodeoxyglucose uptake by using serial positron emission tomography and computed tomography in patients with stage III nonsmall cell lung cancer.
Xu X; Yu J; Sun X; Yang G; Li K; Fu Z; Han A; Zheng J
Am J Clin Oncol; 2008 Oct; 31(5):470-5. PubMed ID: 18838884
[TBL] [Abstract][Full Text] [Related]
8. 18F-FDG uptake as a biologic prognostic factor for recurrence in patients with surgically resected non-small cell lung cancer.
Higashi K; Ueda Y; Arisaka Y; Sakuma T; Nambu Y; Oguchi M; Seki H; Taki S; Tonami H; Yamamoto I
J Nucl Med; 2002 Jan; 43(1):39-45. PubMed ID: 11801701
[TBL] [Abstract][Full Text] [Related]
9. 18F-FMT uptake seen within primary cancer on PET helps predict outcome of non-small cell lung cancer.
Kaira K; Oriuchi N; Shimizu K; Tominaga H; Yanagitani N; Sunaga N; Ishizuka T; Kanai Y; Mori M; Endo K
J Nucl Med; 2009 Nov; 50(11):1770-6. PubMed ID: 19837768
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of fluorine-18 fluorodeoxyglucose positron emission tomography imaging in patients with advanced-stage non-small-cell lung carcinoma.
Hoang JK; Hoagland LF; Coleman RE; Coan AD; Herndon JE; Patz EF
J Clin Oncol; 2008 Mar; 26(9):1459-64. PubMed ID: 18349396
[TBL] [Abstract][Full Text] [Related]
11. 18F-FDG uptake as a biologic factor predicting outcome in patients with resected non-small-cell lung cancer.
Zhang ZJ; Chen JH; Meng L; Du JJ; Zhang L; Liu Y; Dai HH
Chin Med J (Engl); 2007 Jan; 120(2):125-31. PubMed ID: 17335654
[TBL] [Abstract][Full Text] [Related]
12. Prognostic stratification of stage IIIA-N2 non-small-cell lung cancer after induction chemotherapy: a model based on the combination of morphometric-pathologic response in mediastinal nodes and primary tumor response on serial 18-fluoro-2-deoxy-glucose positron emission tomography.
Dooms C; Verbeken E; Stroobants S; Nackaerts K; De Leyn P; Vansteenkiste J
J Clin Oncol; 2008 Mar; 26(7):1128-34. PubMed ID: 18309948
[TBL] [Abstract][Full Text] [Related]
13. Downregulation of 18F-FDG uptake in PET as an early pharmacodynamic effect in treatment of non-small cell lung cancer with the mTOR inhibitor everolimus.
Nogová L; Boellaard R; Kobe C; Hoetjes N; Zander T; Gross SH; Dimitrijevic S; Pellas T; Eschner W; Schmidt K; Bangard C; Hayes W; Thomas RK; Dietlein M; Giaccone G; Hoekstra OS; Lammertsma AA; Wolf J
J Nucl Med; 2009 Nov; 50(11):1815-9. PubMed ID: 19837761
[TBL] [Abstract][Full Text] [Related]
14. Correlation of the apparent diffusion coefficient (ADC) with the standardized uptake value (SUV) in hybrid 18F-FDG PET/MRI in non-small cell lung cancer (NSCLC) lesions: initial results.
Heusch P; Buchbender C; Köhler J; Nensa F; Beiderwellen K; Kühl H; Lanzman RS; Wittsack HJ; Gomez B; Gauler T; Schuler M; Forsting M; Bockisch A; Antoch G; Heusner TA
Rofo; 2013 Nov; 185(11):1056-62. PubMed ID: 23860802
[TBL] [Abstract][Full Text] [Related]
15. Prediction of short-term survival in patients with advanced nonsmall cell lung cancer following chemotherapy based on 2-deoxy-2-[F-18]fluoro-D-glucose-positron emission tomography: a feasibility study.
Dimitrakopoulou-Strauss A; Hoffmann M; Bergner R; Uppenkamp M; Eisenhut M; Pan L; Haberkorn U; Strauss LG
Mol Imaging Biol; 2007; 9(5):308-17. PubMed ID: 17623254
[TBL] [Abstract][Full Text] [Related]
16. Prognostic relevance of response evaluation using [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with locally advanced non-small-cell lung cancer.
Hoekstra CJ; Stroobants SG; Smit EF; Vansteenkiste J; van Tinteren H; Postmus PE; Golding RP; Biesma B; Schramel FJ; van Zandwijk N; Lammertsma AA; Hoekstra OS
J Clin Oncol; 2005 Nov; 23(33):8362-70. PubMed ID: 16293866
[TBL] [Abstract][Full Text] [Related]
17. Standardised FDG uptake: a prognostic factor for inoperable non-small cell lung cancer.
Borst GR; Belderbos JS; Boellaard R; Comans EF; De Jaeger K; Lammertsma AA; Lebesque JV
Eur J Cancer; 2005 Jul; 41(11):1533-41. PubMed ID: 15953716
[TBL] [Abstract][Full Text] [Related]
18. Comparison of tumor volumes derived from glucose metabolic rate maps and SUV maps in dynamic 18F-FDG PET.
Visser EP; Philippens ME; Kienhorst L; Kaanders JH; Corstens FH; de Geus-Oei LF; Oyen WJ
J Nucl Med; 2008 Jun; 49(6):892-8. PubMed ID: 18483085
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of a cumulative SUV-volume histogram method for parameterizing heterogeneous intratumoural FDG uptake in non-small cell lung cancer PET studies.
van Velden FH; Cheebsumon P; Yaqub M; Smit EF; Hoekstra OS; Lammertsma AA; Boellaard R
Eur J Nucl Med Mol Imaging; 2011 Sep; 38(9):1636-47. PubMed ID: 21617975
[TBL] [Abstract][Full Text] [Related]
20. Repeat 18F-FDG PET for monitoring neoadjuvant chemotherapy in patients with stage III non-small cell lung cancer.
Eschmann SM; Friedel G; Paulsen F; Reimold M; Hehr T; Budach W; Dittmann H; Langen HJ; Bares R
Lung Cancer; 2007 Feb; 55(2):165-71. PubMed ID: 17129635
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]